Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. AKYNZEO
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

AKYNZEO

Medicine - Posted on Dec 18 2020
Active substance (DCI)
  • palonosétron (chlorhydrate de)
  • nétupitant
history (2)
  • 12/16/20

    AKYNZEO (palonosetron (chlorhydrate de) / netupitant)

    Key points Unfavourable opinion for reimbursement in adults for the prevention of acute and delayed nausea and vomiting asso...
    CAV :
    54321
    icône flèche
  • 3/22/17

    AKYNZEO (palonosetron + netupitant), combination setron

    No clinical benefit demonstrated in prevention of nausea and vomiting after highly emetogenic chemotherapy compared with the...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • A04AA55
Manufacturer
VIFOR FRANCE S.A.
Presentation

AKYNZEO 300 mg/0,5 mg, gélule (code CIS : 67693946)
Plaquette(s) aluminium de 1 gélule(s) (CIP : 34009 300 386 2 8)

All our publications
    Cancers - miscellaneous Drug therapy Esophageal and gastrointestinal diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
FH4wpTFS69F6hFRY